Atomwise's machine learning-based drug discovery service raises $123 million – TechCrunch

With a slew of partnerships with large pharmaceutical companies under its belt and the successful spin out of at least one new company, Atomwise has already proved the value of its machine learning platform for discovering and commercializing potential small molecule therapies for a host of conditions. Now the company has raised $123 million in new funding to accelerate its business. "Scaling the technology and scaling the team and scaling what we've been doing with it," says chief executive officer Abe Heifets when asked about what comes next for the eight-year-old business. Atomwise has already signed contracts worth $5.5 billion with corporate partners that include Eli Lilly & Co., Bayer, Hansoh Pharmaceuticals and Bridge Biotherapeutics. Smaller, earlier-stage companies like StemoniX and SEngine Precision Medicine are also using Atomwise's tech.